UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of December 2008
001-33444
(Commission File Number)
Eurand N.V.
(Translation of registrant’s name into English)
Olympic Plaza
Fred. Roeskestraat 123
1076 EE Amsterdam, The Netherlands
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F: Form 20-Fþ Form 40-Fo
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):o
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934: Yeso Noþ
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-
INFORMATION CONTAINED IN THIS FORM 6-K REPORT
Included as Exhibit 1 in this report on Form 6-K is a press release issued by Eurand N.V. (the “Company”) on December 26, 2008, announcing that the Company has been advised by GlaxoSmithKline that the United States Food and Drug Administration has issued a complete response letter for the New Drug Application for EUR-1048.
EXHIBIT INDEX
| 99.1 | | Press release issued on December 26, 2008, titled “FDA Issues Complete Response Letter to GlaxoSmithKline for Eurand’s EUR-1048; GlaxoSmithKline Responds to Complete Response Letter.” |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: December 29, 2008
| | | | | |
| | EURAND N.V.
(Registrant)
| |
| | By: | /s/ Manya S. Deehr | |
| | | Manya S. Deehr | |
| | | Chief Legal Officer and Secretary | |
| |
